Kirk A. Keegan

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety et al. · The Lancet Oncology · 2020 · 412 citations · Full text

Urology, Oncology, Genitourinary Cancer +2

Trends in the Use of Perioperative Chemotherapy for Localized and Locally Advanced Muscle-invasive Bladder Cancer: A Sign of Changing Tides

Zachary Reardon, Sanjay G. Patel, Harras B. Zaid et al. · European Urology · 2014 · 222 citations · Full text

Urology, Surgical Oncology, Changing Tides +6

Histopathology of Surgically Treated Renal Cell Carcinoma: Survival Differences by Subtype and Stage

Kirk A. Keegan, Clayton W. Schupp, Karim Chamie et al. · The Journal of Urology · 2012 · 197 citations

Predicting the Probability of 90-Day Survival of Elderly Patients With Bladder Cancer Treated With Radical Cystectomy

Todd M. Morgan, Kirk A. Keegan, Daniel A. Barocas et al. · The Journal of Urology · 2011 · 113 citations

A randomized trial of ritodrine tocolysis versus expectant management in patients with premature rupture of membranes at 25 to 30 weeks of gestation

Thomas J. Garite, Kirk A. Keegan, Roger K. Freeman et al. · American Journal of Obstetrics and Gynecology · 1987 · 108 citations

Urology, Maternal Health, Randomized Trial +5